Helix, the Silicon Valley company that’s styled itself as an app store for DNA tests, made a splash last week when it announced it had raised $200 million — the latest windfall for a company leveraging a boom in consumer genomics.
But as money sloshes around the industry, there’s an uneasy and unsettled question gnawing at even the most bullish investors: Are these bets going to pay off?
About the Author Reprints
Great reporting and a cool animated DNA/money graphic. You can look at it two ways: 1) money is “poring” into DTC genomics, or 2) investments are going down the well.